| Ytd | -28.79% | |
| 1y | -56.55% |
| Open | 2.08 | Prev Close | 2.06 | Low | 2.05 | High | 2.11 | Mkt Cap | 5.73M |
| Vol | 4.11K | Avg Vol | 245.95K | EPS | 0.65 | P/E | 3.16 | Forward P/E | -0.39 |
| Beta | 0.99 | Short Ratio | 2.45 | Inst. Own | 1.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 2.22 | 200-d Avg | 3.13 | 1yr Est | 6.00 |
PCSA News
Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r
Dow Jones falls 800+ pts; energy shares up 2.6%; General Dynamics beats earnings estimates; Verra Mo
US stocks mostly lower, Dow Jones falls 400+ pts. Energy shares up 3%. Procter & Gamble shares d
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday'
Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday'
Interim safety and efficacy data to be reported in Q1VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE
Processa Pharmaceuticals' stock jumps after Phase 2 data show higher capecitabine exposure witho
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposu
On December 12, 2025, Processa Pharmaceuticals, Inc. (the "Company") filed with the Secretar
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing
Processa Pharmaceuticals shares jumped 37.5% after hours following a strong regular session, despite
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCS
Processa Pharma (NASDAQ:PCSA) reported quarterly losses of $(0.25) per share which missed the analys
